Novo Nordisk shares plunge 9% after Alzheimer's drug trial fails to hit key target
Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal.
Source link
